111 related articles for article (PubMed ID: 15796183)
1. In vitro antiproliferation in prostate cancer cell lines with cytostatics and combinations with resistance modifiers.
Pintér O; Mucsi I; Molnár J
In Vivo; 2005; 19(1):253-9. PubMed ID: 15796183
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Res Commun Mol Pathol Pharmacol; 2004; 115-116():251-64. PubMed ID: 17564322
[TBL] [Abstract][Full Text] [Related]
4. Anti-androgen-independent prostate cancer effects of ginsenoside metabolites in vitro: mechanism and possible structure-activity relationship investigation.
Li W; Liu Y; Zhang JW; Ai CZ; Xiang N; Liu HX; Yang L
Arch Pharm Res; 2009 Jan; 32(1):49-57. PubMed ID: 19183876
[TBL] [Abstract][Full Text] [Related]
5. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Yen WC; Lamph WW
Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin.
Sánchez AM; Sánchez MG; Malagarie-Cazenave S; Olea N; Díaz-Laviada I
Apoptosis; 2006 Jan; 11(1):89-99. PubMed ID: 16374544
[TBL] [Abstract][Full Text] [Related]
7. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
[TBL] [Abstract][Full Text] [Related]
8. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
[TBL] [Abstract][Full Text] [Related]
9. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines.
Copeland RL; Das JR; Bakare O; Enwerem NM; Berhe S; Hillaire K; White D; Beyene D; Kassim OO; Kanaan YM
Anticancer Res; 2007; 27(3B):1537-46. PubMed ID: 17595773
[TBL] [Abstract][Full Text] [Related]
11. Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines in vitro.
Kulcsár G
Cancer Biother Radiopharm; 2009 Feb; 24(1):67-80. PubMed ID: 19243249
[TBL] [Abstract][Full Text] [Related]
12. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
13. In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells.
Gyémánt N; Tanaka M; Antus S; Hohmann J; Csuka O; Mándoky L; Molnár J
In Vivo; 2005; 19(2):367-74. PubMed ID: 15796199
[TBL] [Abstract][Full Text] [Related]
14. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
15. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
17. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effect of polyphenols and sterols of virgin argan oil on human prostate cancer cell lines.
Bennani H; Drissi A; Giton F; Kheuang L; Fiet J; Adlouni A
Cancer Detect Prev; 2007; 31(1):64-9. PubMed ID: 17174037
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
Andrews P; Zhao X; Allen J; Li F; Chang M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
[TBL] [Abstract][Full Text] [Related]
20. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro].
Zhang H; Lü JJ; Gao QZ; Zhang J
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):382-5. PubMed ID: 16638347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
